yttrium-90-ibritumomab tiuxetan

Known as: yttrium Y90 ibritumomab tiuxetan, Y90-labeled ibritumomab tiuxetan, Yttrium Y 90 Ibritumomab Tiuxetan 
A radiolabeled monoclonal antibody that is used to treat certain types of B-cell non-Hodgkin lymphoma and is being studied in the treatment of other… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
PURPOSE This phase II trial evaluated the safety and efficacy of yttrium-90 ((90)Y)-ibritumomab tiuxetan in patients with… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
A prospective, multicenter, nonrandomized phase 2 trial was conducted to evaluate the efficacy and safety of a single dose of… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2007
2007
BACKGROUND Therapeutic options for refractory or recurrent primary central nervous system lymphoma (PCNSL) are limited. The blood… (More)
Is this relevant?
2007
2007
There is no data on safety and efficacy of a second course of ibritumomab tiuxetan. In this work, data on patients with B-cell… (More)
Is this relevant?
2005
2005
Yttrium-90 ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals Corp., San Diego, CA) is the first radioimmunotherapy agent… (More)
Is this relevant?
2004
2004
BACKGROUND (90)Y ibritumomab tiuxetan is a radioimmunotherapeutic construct that is reported to be an effective treatment for… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
We previously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
PURPOSE Radioimmunotherapy (RIT) with yttrium-90 ((90)Y)-labeled anti-CD20 antibody ((90)Y ibritumomab tiuxetan; Zevalin, IDEC… (More)
Is this relevant?
Review
2003
Review
2003
90Y ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, Cambridge, MA), the first radioimmunotherapeutic agent approved by the US… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Dosimetry studies in patients with non-Hodgkin’s lymphoma were performed to estimate the radiation absorbed dose to normal organs… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?